145 related articles for article (PubMed ID: 35776258)
1. Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer.
Flanagan MR; Doody DR; Voutsinas J; Wu Q; Banda K; Sharifi N; Li CI; Gadi VK
Ann Surg Oncol; 2022 Oct; 29(11):7194-7201. PubMed ID: 35776258
[TBL] [Abstract][Full Text] [Related]
2. Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer.
Kruse ML; Patel M; McManus J; Chung YM; Li X; Wei W; Bazeley PS; Nakamura F; Hardaway A; Downs E; Chandarlapaty S; Thomas M; Moore HC; Budd GT; Tang WHW; Hazen SL; Bernstein A; Nik-Zainal S; Abraham J; Sharifi N
JCI Insight; 2021 Oct; 6(20):. PubMed ID: 34520399
[TBL] [Abstract][Full Text] [Related]
3. Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer.
McManus JM; Vargas R; Bazeley PS; Schumacher FR; Sharifi N
JNCI Cancer Spectr; 2022 Sep; 6(5):. PubMed ID: 35947687
[TBL] [Abstract][Full Text] [Related]
4. HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Hearn JWD; Sweeney CJ; Almassi N; Reichard CA; Reddy CA; Li H; Hobbs B; Jarrard DF; Chen YH; Dreicer R; Garcia JA; Carducci MA; DiPaola RS; Sharifi N
JAMA Oncol; 2020 Apr; 6(4):e196496. PubMed ID: 32053149
[TBL] [Abstract][Full Text] [Related]
5.
Zein J; Gaston B; Bazeley P; DeBoer MD; Igo RP; Bleecker ER; Meyers D; Comhair S; Marozkina NV; Cotton C; Patel M; Alyamani M; Xu W; Busse WW; Calhoun WJ; Ortega V; Hawkins GA; Castro M; Chung KF; Fahy JV; Fitzpatrick AM; Israel E; Jarjour NN; Levy B; Mauger DT; Moore WC; Noel P; Peters SP; Teague WG; Wenzel SE; Erzurum SC; Sharifi N
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2187-2193. PubMed ID: 31932420
[TBL] [Abstract][Full Text] [Related]
6. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
Hearn JWD; AbuAli G; Reichard CA; Reddy CA; Magi-Galluzzi C; Chang KH; Carlson R; Rangel L; Reagan K; Davis BJ; Karnes RJ; Kohli M; Tindall D; Klein EA; Sharifi N
Lancet Oncol; 2016 Oct; 17(10):1435-1444. PubMed ID: 27575027
[TBL] [Abstract][Full Text] [Related]
7. HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond.
Sabharwal N; Sharifi N
Endocrinology; 2019 Sep; 160(9):2180-2188. PubMed ID: 31271415
[TBL] [Abstract][Full Text] [Related]
8. Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.
McKay RR; Nelson TJ; Pagadala MS; Teerlink CC; Gao A; Bryant AK; Agiri FY; Guram K; Thompson RF; Pridgen KM; Seibert TM; Lee KM; Carter H; Lynch JA; Hauger RL; Rose BS
JAMA Netw Open; 2024 Mar; 7(3):e242976. PubMed ID: 38506808
[TBL] [Abstract][Full Text] [Related]
9. Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
Thomas L; Sharifi N
Urology; 2020 Nov; 145():13-21. PubMed ID: 32866512
[TBL] [Abstract][Full Text] [Related]
10. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
[TBL] [Abstract][Full Text] [Related]
11. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
[TBL] [Abstract][Full Text] [Related]
12. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
[TBL] [Abstract][Full Text] [Related]
13. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
[TBL] [Abstract][Full Text] [Related]
14. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
15. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
[TBL] [Abstract][Full Text] [Related]
16. HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.
Hettel D; Sharifi N
Nat Rev Urol; 2018 Mar; 15(3):191-196. PubMed ID: 29231195
[TBL] [Abstract][Full Text] [Related]
17. Expression of 3β-Hydroxysteroid Dehydrogenase Type 1 in Breast Cancer is Associated with Poor Prognosis Independent of Estrogen Receptor Status.
Chang YC; Chen CK; Chen MJ; Lin JC; Lin CH; Huang WC; Cheng SP; Chen SN; Liu CL
Ann Surg Oncol; 2017 Dec; 24(13):4033-4041. PubMed ID: 28744792
[TBL] [Abstract][Full Text] [Related]
18. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
Alyamani M; Emamekhoo H; Park S; Taylor J; Almassi N; Upadhyay S; Tyler A; Berk MP; Hu B; Hwang TH; Figg WD; Peer CJ; Chien C; Koshkin VS; Mendiratta P; Grivas P; Rini B; Garcia J; Auchus RJ; Sharifi N
J Clin Invest; 2018 Aug; 128(8):3333-3340. PubMed ID: 29939161
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer.
Stangl-Kremser J; Lemberger U; Hassler MR; Bruchbacher A; Ilijazi D; Garstka N; Kramer G; Haitel A; Abufaraj M; Shariat SF
Clin Genitourin Cancer; 2019 Oct; 17(5):389-394. PubMed ID: 31331867
[TBL] [Abstract][Full Text] [Related]
20. ASO Author Reflections: Inheritance of Adrenal Permissive HSD3B1 Genotype Negatively Impacts Outcomes in Hormone Receptor-Positive Postmenopausal Breast Cancer.
Flanagan MR; Sharifi N; Gadi VK
Ann Surg Oncol; 2022 Oct; 29(11):7202-7203. PubMed ID: 35819571
[No Abstract] [Full Text] [Related]
[Next] [New Search]
